International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation

NCT ID: NCT01630434

Last Updated: 2023-04-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, international, multi-center, randomized controlled trial comparing preservation of donor lungs using OCS-Lung perfusion device (Treatment Group) to cold flush and storage (Control Group).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Preservation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OCS Lung (Treatment Group)

The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.

Group Type EXPERIMENTAL

OCS Lung

Intervention Type DEVICE

OCS Lung will be used to preserve the donor lungs (Treatment Group).

Cold flush and storage (Control Group)

Donor lungs will be preserved using cold flush and storage (control group)

Group Type ACTIVE_COMPARATOR

Cold flush and storage

Intervention Type DEVICE

Donor lungs will preserved using standard cold flush and storage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OCS Lung

OCS Lung will be used to preserve the donor lungs (Treatment Group).

Intervention Type DEVICE

Cold flush and storage

Donor lungs will preserved using standard cold flush and storage

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Commercially available cold preservation solution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Registered primary double-lung transplant candidate
* Age \> or equal to 18
* Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information

Exclusion Criteria

* Prior solid organ or bone marrow transplant
* Single lung recipient
* Multiple organ transplant recipient
* Chronic use of hemodialysis or diagnosis of chronic renal insufficiency
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TransMedics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abbas Ardehali, MD

Role: STUDY_DIRECTOR

Ronald Reagan Medical Center, UCLA

Dirk van Raemodonck, MD

Role: STUDY_DIRECTOR

UZ Leuven, Belgium

Gregor Warnecke, MD

Role: STUDY_DIRECTOR

Hannover Medical Center, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States

Site Status

University of California at Los Angeles

Los Angeles, California, United States

Site Status

University of California at San Francisco

San Francisco, California, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

St. Vincent's Hospital

Darlinghurst, New South Wales, Australia

Site Status

Hospitals Leuven

Leuven, , Belgium

Site Status

University of Alberta

Edmonton, Alberta, Canada

Site Status

University Hospitals of Marseille

Marseille, , France

Site Status

Groupe Hospitalier Hopitaux Universitaries

Paris, , France

Site Status

N.H.C Hospital Civil

Strasbourg, , France

Site Status

German Heart Institute Berlin

Berlin, , Germany

Site Status

Universitäres Herzzentrum Hamburg GmbH

Hamburg, , Germany

Site Status

Hannover Medical School

Hanover, , Germany

Site Status

University of Padua

Padua, , Italy

Site Status

University Puerta de Hierro Hospital

Madrid, , Spain

Site Status

Papworth Hospital

Cambridge, , United Kingdom

Site Status

Harefield Hospital

Middlesex, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Belgium Canada France Germany Italy Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Warnecke G, Van Raemdonck D, Smith MA, Massard G, Kukreja J, Rea F, Loor G, De Robertis F, Nagendran J, Dhital KK, Moradiellos Diez FJ, Knosalla C, Bermudez CA, Tsui S, McCurry K, Wang IW, Deuse T, Leseche G, Thomas P, Tudorache I, Kuhn C, Avsar M, Wiegmann B, Sommer W, Neyrinck A, Schiavon M, Calabrese F, Santelmo N, Olland A, Falcoz PE, Simon AR, Varela A, Madsen JC, Hertz M, Haverich A, Ardehali A. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med. 2018 May;6(5):357-367. doi: 10.1016/S2213-2600(18)30136-X. Epub 2018 Apr 9.

Reference Type DERIVED
PMID: 29650408 (View on PubMed)

Bozso S, Freed D, Nagendran J. Successful transplantation of extended criteria lungs after prolonged ex vivo lung perfusion performed on a portable device. Transpl Int. 2015 Feb;28(2):248-50. doi: 10.1111/tri.12474. Epub 2014 Oct 27. No abstract available.

Reference Type DERIVED
PMID: 25284600 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OCS-LUN-03-2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

10°C vs 4°C Lung Preservation RCT
NCT05898776 RECRUITING NA
RELIVE Informed Consent Study
NCT01742234 COMPLETED